Association of Serum Visfatin Levels with Coronary Artery Disease and Biochemical Parameters in Patients Undergoing Maintenance Hemodialysis

Background

Cardiovascular disease is a major cause of morbidity and mortality in patients with end-stage kidney disease receiving maintenance hemodialysis. Visfatin is a pro-inflammatory adipokine involved in metabolic and inflammatory pathways; however, its relationship with established coronary artery disease (CAD) in hemodialysis patients remains uncertain. This study evaluated the associations of serum visfatin concentrations with hemodialysis status, clinically documented CAD, and selected metabolic and biochemical parameters.